TCP
FOLD

Tourbillon Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Tourbillon Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,500,000
Closed -$22.6M – 80
2018
Q1 		$22.6M Buy
1,500,000
+800,000
+114% +$12.2M 0.9% 40
2017
Q4 		$10.1M Buy
700,000
+450,000
+180% +$6.18M 0.37% 39
2017
Q3 		$3.77M Buy
+250,000
New +$3.31M 0.09% 51

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tourbillon Capital Partners's FOLD Position: Q4 2018 in Review

Tourbillon Capital Partners sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 1,414,130 shares — an estimated $17.1M sold.

Tourbillon Capital Partners first reported a position in FOLD in Q4 2014 and held it in 8 quarters. The position peaked at $47.3M in Q4 2017. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Tourbillon Capital Partners reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 1,414,130 Amicus Therapeutics shares in Q4 2018, an estimated $17.1M.
  • Tourbillon Capital Partners first reported a position in Amicus Therapeutics in Q4 2014 and held it in 8 quarters.
  • Tourbillon Capital Partners's Amicus Therapeutics position peaked at $47.3M in Q4 2017.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Tourbillon Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.